These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 19791828)

  • 1. Saxagliptin.
    Dhillon S; Weber J
    Drugs; 2009 Oct; 69(15):2103-14. PubMed ID: 19791828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU.
    Yang LP
    Drugs; 2012 Jan; 72(2):229-48. PubMed ID: 22221000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Saxagliptin: a clinical review in the treatment of type 2 diabetes mellitus.
    Kania DS; Gonzalvo JD; Weber ZA
    Clin Ther; 2011 Aug; 33(8):1005-22. PubMed ID: 21802144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus.
    Karyekar CS; Ravichandran S; Allen E; Fleming D; Frederich R
    Clin Interv Aging; 2013; 8():419-30. PubMed ID: 23626461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term 4-year safety of saxagliptin in drug-naive and metformin-treated patients with Type 2 diabetes.
    Rosenstock J; Gross JL; Aguilar-Salinas C; Hissa M; Berglind N; Ravichandran S; Fleming D
    Diabet Med; 2013 Dec; 30(12):1472-6. PubMed ID: 23802840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
    Deacon CF; Holst JJ
    Adv Ther; 2009 May; 26(5):488-99. PubMed ID: 19444391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinically relevant reductions in HbA1c without hypoglycaemia: results across four studies of saxagliptin.
    Karyekar CS; Frederich R; Ravichandran S
    Int J Clin Pract; 2013 Aug; 67(8):759-67. PubMed ID: 23795975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus and cardiovascular disease history or cardiovascular risk factors: results of a pooled analysis of phase 3 clinical trials.
    Cook W; Bryzinski B; Slater J; Frederich R; Allen E
    Postgrad Med; 2013 May; 125(3):145-54. PubMed ID: 23748515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical overview of saxagliptin for Type 2 diabetes management.
    Rosenstock J
    Expert Rev Endocrinol Metab; 2010 Nov; 5(6):809-823. PubMed ID: 30780831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin.
    Barnett AH; Charbonnel B; Donovan M; Fleming D; Chen R
    Curr Med Res Opin; 2012 Apr; 28(4):513-23. PubMed ID: 22313154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sitagliptin.
    Lyseng-Williamson KA
    Drugs; 2007; 67(4):587-97. PubMed ID: 17352516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of saxagliptin as an add-on to oral monotherapy in the phase 3 clinical development program: predictive factors of the treatment response in type 2 diabetes.
    Gautier JF; Sauvanet JP
    Ann Endocrinol (Paris); 2011 Sep; 72(4):287-295. PubMed ID: 21777901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
    Pratley RE; Nauck M; Bailey T; Montanya E; Cuddihy R; Filetti S; Thomsen AB; Søndergaard RE; Davies M;
    Lancet; 2010 Apr; 375(9724):1447-56. PubMed ID: 20417856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes.
    Thomsen RW; Baggesen LM; Søgaard M; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
    Diabetologia; 2015 Oct; 58(10):2247-53. PubMed ID: 26277380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials.
    Gilbert MP; Pratley RE
    Front Endocrinol (Lausanne); 2020; 11():178. PubMed ID: 32308645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sitagliptin: a novel agent for the management of type 2 diabetes mellitus.
    Pham DQ; Nogid A; Plakogiannis R
    Am J Health Syst Pharm; 2008 Mar; 65(6):521-31. PubMed ID: 18319497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial.
    Chacra AR; Tan GH; Apanovitch A; Ravichandran S; List J; Chen R;
    Int J Clin Pract; 2009 Sep; 63(9):1395-406. PubMed ID: 19614786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes.
    Sharma MD
    Ther Clin Risk Manag; 2010 May; 6():233-7. PubMed ID: 20526441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.